DE69840497D1 - Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen - Google Patents
Verwendung von Aplidine zur Behandlung von kardiovaskulären ErkrankungenInfo
- Publication number
- DE69840497D1 DE69840497D1 DE69840497T DE69840497T DE69840497D1 DE 69840497 D1 DE69840497 D1 DE 69840497D1 DE 69840497 T DE69840497 T DE 69840497T DE 69840497 T DE69840497 T DE 69840497T DE 69840497 D1 DE69840497 D1 DE 69840497D1
- Authority
- DE
- Germany
- Prior art keywords
- aplidine
- treatment
- cardiovascular diseases
- useful
- dehydrodidemnin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 title abstract 5
- 229950008499 plitidepsin Drugs 0.000 title abstract 5
- 108010049948 plitidepsin Proteins 0.000 title abstract 5
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 abstract 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4580397P | 1997-05-07 | 1997-05-07 | |
| PCT/US1998/009238 WO1998050048A1 (en) | 1997-05-07 | 1998-05-06 | Aplidine as an l-type calcium channel enhancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69840497D1 true DE69840497D1 (de) | 2009-03-12 |
Family
ID=21939974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69840497T Expired - Fee Related DE69840497D1 (de) | 1997-05-07 | 1998-05-06 | Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6030943A (de) |
| EP (1) | EP0981352B8 (de) |
| JP (1) | JP4327260B2 (de) |
| AT (1) | ATE421329T1 (de) |
| AU (1) | AU740598B2 (de) |
| CA (1) | CA2288639A1 (de) |
| DE (1) | DE69840497D1 (de) |
| ES (1) | ES2321462T3 (de) |
| WO (1) | WO1998050048A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8922026D0 (en) | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| GB9803448D0 (en) * | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| MXPA02004862A (es) * | 1999-11-15 | 2003-01-28 | Pharma Mar Sa | Tratamiento de aplidina para canceres. |
| UA76718C2 (uk) * | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| RU2003113210A (ru) * | 2000-10-12 | 2004-11-27 | Фарма Мар, С.А. (Es) | Лечение раковых заболеваний |
| FI20010233A0 (fi) * | 2001-02-08 | 2001-02-08 | Orion Corp | Menetelmä sydämen vajaatoiminnan hoitoon |
| US20030049258A1 (en) * | 2001-09-11 | 2003-03-13 | Martin Ungerer | Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
| ATE411036T1 (de) * | 2001-10-19 | 2008-10-15 | Pharma Mar Sa | Verwendung von aplidine in der behandlung von pankreaskrebs |
| SI1603584T1 (sl) * | 2003-03-12 | 2009-02-28 | Dana Farber Cancer Inst Inc | Aplidin za zdravljenje multiple mieloma |
| CN101579520A (zh) * | 2003-03-12 | 2009-11-18 | 达纳-法伯癌症协会有限公司 | 用于多发性骨髓瘤的治疗的aplidine |
| ME02450B (me) * | 2006-02-28 | 2016-09-20 | Pharma Mar Sa | POBOLJŠANO LIJEČENJE MULTlPLOG MIJELOMA |
| US20100240595A1 (en) * | 2007-10-19 | 2010-09-23 | Pharma Mar ,S.A. | Improved Antitumoral Treatments |
| CN101965191A (zh) * | 2008-03-07 | 2011-02-02 | 法马马有限公司 | 改善的抗癌治疗 |
| KR101679082B1 (ko) | 2008-03-17 | 2016-11-23 | 더 스크립스 리서치 인스티튜트 | 유도 만능 줄기 세포 생성을 위한 화학적 및 유전적 조합 접근법 |
| EP4438734A2 (de) | 2010-06-14 | 2024-10-02 | The Scripps Research Institute | Neuprogrammierung von zellen in ein neues fett |
| JP6182456B2 (ja) | 2010-12-22 | 2017-08-23 | フェイト セラピューティクス，インコーポレイテッド | 単細胞選別のための細胞培養プラットホームおよびｉＰＳＣの再プログラミングの増強 |
| WO2013041969A2 (en) | 2011-09-21 | 2013-03-28 | King Abdullah University Of Science And Technology | Didemnin biosynthetic gene cluster in tistrella mobilis |
| KR20240091064A (ko) | 2014-03-04 | 2024-06-21 | 페이트 세러퓨틱스, 인코포레이티드 | 개선된 재프로그래밍 방법 및 세포 배양 플랫폼 |
| CN117737124A (zh) | 2015-10-16 | 2024-03-22 | 菲特治疗公司 | 用于诱导和维护基态多能性的平台 |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| CN115594739A (zh) * | 2021-06-28 | 2023-01-13 | 浙江珲达生物科技有限公司（Cn） | 一种dehydrodidemnin B类化合物的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| US5580871A (en) * | 1992-11-20 | 1996-12-03 | The Dupont Merck Pharmaceutical Company | 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity |
-
1998
- 1998-05-06 CA CA002288639A patent/CA2288639A1/en not_active Abandoned
- 1998-05-06 WO PCT/US1998/009238 patent/WO1998050048A1/en active IP Right Grant
- 1998-05-06 JP JP54844198A patent/JP4327260B2/ja not_active Expired - Fee Related
- 1998-05-06 DE DE69840497T patent/DE69840497D1/de not_active Expired - Fee Related
- 1998-05-06 AT AT98920293T patent/ATE421329T1/de not_active IP Right Cessation
- 1998-05-06 US US09/073,288 patent/US6030943A/en not_active Expired - Fee Related
- 1998-05-06 EP EP98920293A patent/EP0981352B8/de not_active Expired - Lifetime
- 1998-05-06 AU AU72900/98A patent/AU740598B2/en not_active Ceased
- 1998-05-06 ES ES98920293T patent/ES2321462T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2288639A1 (en) | 1998-11-12 |
| AU740598B2 (en) | 2001-11-08 |
| ATE421329T1 (de) | 2009-02-15 |
| EP0981352B8 (de) | 2009-06-17 |
| EP0981352A1 (de) | 2000-03-01 |
| ES2321462T3 (es) | 2009-06-05 |
| WO1998050048A1 (en) | 1998-11-12 |
| EP0981352A4 (de) | 2007-04-25 |
| EP0981352B1 (de) | 2009-01-21 |
| JP4327260B2 (ja) | 2009-09-09 |
| JP2001526657A (ja) | 2001-12-18 |
| AU7290098A (en) | 1998-11-27 |
| US6030943A (en) | 2000-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69840497D1 (de) | Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen | |
| DE69434431D1 (de) | Methoden zur behandlung von muskelerkrankungen und muskelstörungen | |
| HUP0104718A2 (hu) | Mikronizált eplerenon kompozíciók és eljárás az előállításukra | |
| DE69738615D1 (de) | Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt | |
| ES2060951T5 (es) | Azaindenos. | |
| DE69921156D1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| NO991732L (no) | Nye heterocyklylmetylsubstituerte pyrazolderivater | |
| EA200000723A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| NO992400L (no) | Nye substituerte pyrazolderivater | |
| ATE462427T1 (de) | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren | |
| DE69827651D1 (de) | Verwendung von tempol zur behandlung von essentiellem hochdruck | |
| DK1268498T3 (da) | Kardioprotektive phosphater | |
| ATE439833T1 (de) | Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten | |
| ATE211391T1 (de) | Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung | |
| DE60015508D1 (de) | C-16 ungesätigte fp-selektive prostaglandin analoge | |
| ATE192923T1 (de) | Verwendung von boswelliasäure zur behandlung von hirntumoren | |
| ATE422892T1 (de) | Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle | |
| ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| DE60219940D1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| TR199700963T1 (xx) | Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi. | |
| ATE151774T1 (de) | Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen | |
| EA199900006A1 (ru) | Препарат и способ для лечения застоной сердечной недостаточности | |
| DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| ATE486594T1 (de) | Methode zur behandlung von herzinsuffizienz | |
| DE60216090D1 (de) | Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |